GLP-1 weight loss drugs linked to heightened GI risks, says new study

FHS
October 5, 2023
11:04 pm

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug | Psychedelic Invest

TEL AVIV, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the

August 7, 2024

BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers

BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the

February 14, 2024

Saving rural psychiatry services will require higher Medicaid payments

If there were ever to be an empty bed in the stress unit my psychiatrist dad manages, I’m certain he would admit himself. He runs

May 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.